Illegal Drugs and Nutrition in Undergraduate Students

Re, Davis; Nd, Midalia; Dh, Curnow

doi:10.5694/j.1326-5377.1978.tb142008.x

Cited by 6 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the light of current knowledge, it is hard to indicate a putative linkage between cannabis use and Hcy metabolism. There are studies showing the association between cannabis use and low folate levels in pregnant women (Knight et al 1994 ) and undergraduate students (Davis et al 1978 ). These authors suggested that low folate level occurs most likely due to nutritional constraint.…”

Section: Discussionmentioning

confidence: 99%

“…There are also studies showing low folate level due to cannabis abuse in pregnant women (Knight et al 1994) and undergraduate students (Davis et al 1978). However, the influence of cannabis on plasma levels of Hcy, vitamin B12 and folate has not been investigated so far.…”

Section: Introductionmentioning

confidence: 99%

“…A number of environmental factors including alcohol consumption, cigarette smoking and various medications may influence one-carbon metabolism (Nygard et al 1995 ; de Bree et al 2001 ; Dierkes et al 2007 ). There are also studies showing low folate level due to cannabis abuse in pregnant women (Knight et al 1994 ) and undergraduate students (Davis et al 1978 ). However, the influence of cannabis on plasma levels of Hcy, vitamin B12 and folate has not been investigated so far.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Elevated homocysteine level in first-episode schizophrenia patients—the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse

et al. 2014

View full text Add to dashboard Cite

Accumulating evidence indicates that elevated homocysteine (Hcy) level occurs in first-episode schizophrenia (FES) patients. We included 56 FES patients and 53 healthy controls (HC). Plasma level of Hcy was significantly higher in FES patients than HC (p = 0.044). In addition, plasma levels of high-density lipoproteins (HDL) and folate were significantly lower in FES than in HC (p < 0.001). Positive family history of schizophrenia was associated with lower plasma HDL (p = 0.041) and vitamin B12 (p = 0.017), as well as higher level of Hcy (p = 0.017). Patients with FES, who abused cannabis, had higher levels of Hcy (p = 0.017), as well as lower levels of vitamin B12 (p = 0.017) and HDL (p = 0.041). Plasma Hcy negatively correlated with duration of untreated psychosis (r = −0.272, p = 0.042). There was a positive correlation between Hcy level and the severity of negative symptoms (r = 0.363, p = 0.006) and general psychopathology (r = 0.349, p = 0.008) assessed using Positive and Negative Syndrome Scale (PANSS). Vitamin B12 level was negatively associated with the severity of negative symptoms (r = −0.406, p = 0.002), while folate level negatively correlated with general psychopathology score (r = −0.365, p = 0.006) in PANSS. These results indicate that the severity of one-carbon metabolism alterations and HDL deficiency might be associated with family history of schizophrenia and cannabis abuse. Lower vitamin B12 and folate along with elevated Hcy may influence the severity of FES psychopathology.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated homocysteine level in first-episode schizophrenia patients—the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The study of Guillem et al [ 41 ] confirms the high mood and anxiety disorders comorbidity among dependent users of cannabis. Also there are also studies that is showing low folate level due to cannabis abuse in pregnant women [ 42 ] and undergraduate students [ 43 ]. Cannabis abuse is associated with higher Homocysteine, as well as lower HDL and vitamin B12 levels first-episode schizophrenia [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

CT genotype of 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is protector factor of major depressive disorder in the Tunisian population: a case control study

et al. 2016

View full text Add to dashboard Cite

BackgroundMajor depressive disorder (MDD) is a common psychiatric disorder with considerable mortality. Death from unnatural causes, largely suicidal or quasi-suicidal, has a particularly high risk for the functional disorders, especially depression and schizophrenia. One of the prospective risk factors for this disease is hyperhomocysteinemia and folate deficiency. The methylenetetrahydrofolate reductase (MTHFR) gene encodes for a 5-methylenetetrahydrofolate reductase involved in folate metabolism and neurotransmitter synthesis. The aim of this research is to study the association between the C677T polymorphism of MTHFR gene and depression in Tunisian population, to explore their relationship with clinical and therapeutic characteristics of this disease. And it may lead to discover a novel marker to identify a patient with a higher risk of development of depressive disorder to be. This marker can be used for better therapeutic management and prevent disease installation.MethodsOur study included 208 depressive patients, 187 controls aged between 44.1 ± 13.5 and 38.9 ± 13.2 years, respectively. MTHFR gene polymorphisms were determined by PCR–RFLP (polymerase chain reaction–restriction fragment length polymorphism).ResultsNo significant difference was detected in the distribution of the genotype frequencies of MTHFR C677T polymorphisms (χ2 = 5.443, df = 2, p = 0.066) between patients and controls. But when we study the risk of these genotypes, CT genotype is significantly more frequent in controls compared to patients, it may be a protection from depression (OR = 0.655, CI 95 % = 0.432–0.995, p = 0.047, OR* = 0.638, CI 95 %* = 0.415–0.983, p* = 0.04, before and after adjustment). Women, TT Genotype can increase four times the risk to be depressive. Addictive behavior seems to be associated with CT genotype and there was no significant association between clinical and therapeutic characteristics and this polymorphism.ConclusionThis paper is the first study to prove that CT genotype of MTHFR C677T polymorphism may protect from depression and TT genotype seems to be associated with women’s depression. Further studies are required with other polymorphisms and biochemical factors that must be investigated to clarify the implication of MTHFR C677T polymorphism in the pathophysiology of depression.

show abstract

“…. Αν και ορισμένες νευροχημικές επιδράσεις των κανναβινοειδών ακολουθούν ένα απρόβλεπτο προφίλ, είναι εμφανές ότι τα εξωγενή κανναβινοειδή τροποποιούν την «Ο ρόλος των CB 1 υποδοχέων στις νευροβιολογικές δράσεις εξαρτησιογόνων φαρμάκων» και καταληψία στις υψηλές δόσεις(Davis et al 1978;Drews et al 2005;Rodvelt et al 2007;Sanudo-Pena et al 2000;Sulcova et al 1998). Εντούτοις, υπάρχει μια έλλειψη πληροφοριών για τη αντίστοιχη διφασική δράση των κανναβινοειδών σε νευροβιολογικούς δείκτες που σχετίζονται με το μηχανισμό δράσης τους.…”

unclassified

Ο Ρόλος Των CB1 Υποδοχέων Των Κανναβινοειδών Στις Νευροβιολογικές Δράσεις Εξαρτησιογόνων Φαρμάκων

Polissidis¹,

Πολυσίδη²

View full text Add to dashboard Cite

show abstract

Illegal Drugs and Nutrition in Undergraduate Students

Cited by 6 publications

References 11 publications

Elevated homocysteine level in first-episode schizophrenia patients—the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse

Elevated homocysteine level in first-episode schizophrenia patients—the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse

CT genotype of 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is protector factor of major depressive disorder in the Tunisian population: a case control study

Ο Ρόλος Των CB1 Υποδοχέων Των Κανναβινοειδών Στις Νευροβιολογικές Δράσεις Εξαρτησιογόνων Φαρμάκων

Contact Info

Product

Resources

About